Gilead Sciences, Inc. (GILD) Receives $85.22 Consensus Price Target from Analysts

Gilead Sciences, Inc. (NASDAQ:GILD) has earned an average recommendation of “Buy” from the thirty-three brokerages that are presently covering the firm, MarketBeat.com reports. One research analyst has rated the stock with a sell rating, thirteen have given a hold rating and eighteen have assigned a buy rating to the company. The average 12-month price target among brokerages that have issued a report on the stock in the last year is $85.27.

A number of research analysts have issued reports on GILD shares. Jefferies Group restated a “hold” rating and set a $93.00 target price on shares of Gilead Sciences in a research report on Wednesday, October 4th. Bank of America decreased their target price on shares of Gilead Sciences from $87.00 to $86.00 and set a “neutral” rating on the stock in a research report on Wednesday, October 4th. Oppenheimer started coverage on shares of Gilead Sciences in a research report on Thursday, October 5th. They set a “market perform” rating on the stock. CIBC assumed coverage on shares of Gilead Sciences in a research report on Thursday, October 5th. They set a “market perform” rating on the stock. Finally, Leerink Swann increased their price target on shares of Gilead Sciences from $87.00 to $89.00 and gave the stock a “market perform” rating in a research report on Thursday, October 5th.

Shares of Gilead Sciences (NASDAQ:GILD) traded down $3.38 on Friday, reaching $83.91. 6,881,556 shares of the company were exchanged, compared to its average volume of 9,064,769. Gilead Sciences has a twelve month low of $63.76 and a twelve month high of $89.54. The firm has a market cap of $109,450.00, a price-to-earnings ratio of 9.53, a P/E/G ratio of -1.96 and a beta of 1.13. The company has a debt-to-equity ratio of 1.10, a quick ratio of 3.56 and a current ratio of 3.68.

Gilead Sciences (NASDAQ:GILD) last announced its earnings results on Thursday, October 26th. The biopharmaceutical company reported $2.27 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $2.13 by $0.14. Gilead Sciences had a net margin of 42.22% and a return on equity of 57.15%. The firm had revenue of $6.51 billion for the quarter, compared to analyst estimates of $6.40 billion. During the same quarter in the prior year, the business posted $2.75 EPS. The business’s revenue was down 13.2% compared to the same quarter last year. analysts anticipate that Gilead Sciences will post 8.53 earnings per share for the current year.

In related news, EVP James R. Meyers sold 100,000 shares of the firm’s stock in a transaction on Tuesday, January 16th. The shares were sold at an average price of $80.24, for a total value of $8,024,000.00. Following the completion of the transaction, the executive vice president now directly owns 102,715 shares of the company’s stock, valued at $8,241,851.60. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, EVP Gregg H. Alton sold 30,000 shares of the firm’s stock in a transaction on Thursday, January 11th. The shares were sold at an average price of $79.00, for a total transaction of $2,370,000.00. Following the completion of the transaction, the executive vice president now directly owns 57,114 shares of the company’s stock, valued at $4,512,006. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 503,333 shares of company stock worth $37,834,758. 1.30% of the stock is owned by company insiders.

Several large investors have recently added to or reduced their stakes in GILD. Welch Investments LLC bought a new stake in shares of Gilead Sciences in the third quarter valued at about $108,000. Wealthcare Advisory Partners LLC purchased a new stake in shares of Gilead Sciences during the third quarter worth about $133,000. Horan Capital Advisors LLC. purchased a new stake in shares of Gilead Sciences during the third quarter worth about $144,000. Hanson & Doremus Investment Management grew its stake in shares of Gilead Sciences by 806.5% during the third quarter. Hanson & Doremus Investment Management now owns 1,813 shares of the biopharmaceutical company’s stock worth $147,000 after acquiring an additional 1,613 shares during the last quarter. Finally, Migdal Insurance & Financial Holdings Ltd. purchased a new stake in shares of Gilead Sciences during the second quarter worth about $147,000. Institutional investors and hedge funds own 76.11% of the company’s stock.

COPYRIGHT VIOLATION WARNING: This piece of content was first posted by Week Herald and is the property of of Week Herald. If you are viewing this piece of content on another website, it was copied illegally and reposted in violation of U.S. and international trademark & copyright law. The correct version of this piece of content can be viewed at https://weekherald.com/2018/02/15/gilead-sciences-inc-gild-receives-85-22-consensus-price-target-from-analysts.html.

About Gilead Sciences

Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.

Analyst Recommendations for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply